Hemogenyx Pharmaceuticals Plc

LSE:HEMO Stock Report

Market Cap: UK£16.1m

Hemogenyx Pharmaceuticals Valuation

Is HEMO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HEMO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HEMO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HEMO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HEMO?

Key metric: As HEMO is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for HEMO. This is calculated by dividing HEMO's market cap by their current book value.
What is HEMO's PB Ratio?
PB Ratio5.3x
BookUK£3.06m
Market CapUK£16.10m

Price to Book Ratio vs Peers

How does HEMO's PB Ratio compare to its peers?

The above table shows the PB ratio for HEMO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.1x
OPTI OptiBiotix Health
1.7xn/aUK£12.2m
PBX ProBiotix Health
8xn/aUK£10.3m
SNG Synairgen
1x50.2%UK£9.3m
AREC Arecor Therapeutics
5.6x-1.8%UK£28.3m
HEMO Hemogenyx Pharmaceuticals
5.3xn/aUK£16.1m

Price-To-Book vs Peers: HEMO is expensive based on its Price-To-Book Ratio (5.3x) compared to the peer average (4.1x).

Price to Book Ratio vs Industry

How does HEMO's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.46m
VAL ValiRx
0.6xn/aUS$2.78m
No more companies available in this PB range
HEMO 5.3xIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: HEMO is expensive based on its Price-To-Book Ratio (5.3x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is HEMO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HEMO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate HEMO's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%